Our client-ready Disease Target Assessment (DTA Ready™) models enable teams to generate rigorous assessments of new drug profiles within two weeks of kickoff.

Each model includes a current unmet need analysis and allows teams to generate peak-year patient share estimates immediately upon input of your Target Product Profile (TPP). The analysis is supported by epidemiology assumptions and a competitive landscape that are rapidly developed and aligned with your team at project initiation — ensuring speed without compromising analytical depth or precision.

DTA Ready™ is built for R&D and business development teams operating under tight timelines ahead of key governance, portfolio, or brand decisions.

Below is the list of immediately available models across a variety of oncology indications.